DAFTAR PUSTAKA

1. McPhee SJ and, Ganong WF. Patofisiologi Penyakit Edisi 5. Jakarta, EGC;

2010.
2. Howard IM. The prevention of Foot Ulceration in Diabetic Patients. Phys
Med Rehabil Clin N Am 2009;20(4):9-609.
3. Khallaf A-N, Fathi O, Ayad W, Fawzy A. Diabetic Foot Ulcers: Concervative
Management as Limb Salvage. Egypt, J. Plast. Reconstr. Surgery
2006;30(2):107-111.
4. Frykberg RG, Zgonis T, Amstrong DG, et al. Diabetic Foot Disordes. A
Clinical Practice Guideline (2006 revision). J Foot Ankle Surg 2006;45(5
Suppl):S1-66.
5. International Diabetes Federation. The Global Burden. In: Nigel U, Editors.
Diabetes atlas. 5th ed. Brussels: IDF; 2012.
6. Reiber GE and, Ledoux WR. Epidemiology of Diabetic Foot Ulcers and
Amputations: Evidence for Prevention. In: Williams R, Editors. The Evidence
Base for Diabetes Care. John Wiley & Sons; 2003.
7. Reilly M, Mohler E. Cilostazol: Treatment of Intermittent Claudication. Ann
Pharmacother 2001;35:48-56.
8. Nakamura N, Hamazaki T, Johkaji H, et al. Effects of Cilostazol on Serum
lipid concentrations and plasma fatty acid composition in type 2 Diabetic
Patients with Weripheral Vascular Disease. Clin Exp Med 2003;2(4):180-4.
9. Ahn CW, Lee HC, Park SW, et al. Decrease in Carotid Intima Media
Thickness After 1 Year of Cilostazol Treatment in Patients With Type 2
Diabetes Mellitus. Diabetes Res Clin Pract 2001;52(1):45-53.
10. Miller MS. Pharmacotherapy as Adjunctive Treatment for Serious Foot
Wounds in the Patient with Diabetes: a Case Study. Ostomy Wound Manage
2003;49(4):52-5.
11. Mahameed AA. Peripheral Arterial Disease. Cleveland Clinic publications:
Disease
Management
Project
2009;
(online),
(http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/car
diology/peripheral-arterial-disease/, diakses 21 Juni 2013).

12. Layton M, Goodfield MJD, Ibbotson S, et al. Randomised Trial of Oral

Aspirin for Chronic Venous Leg Ulcers. TheLancet.com 1994; (online), 344:
164-165,
(http://www.thelancet.com/journals/lancet/article/PIIS01406736(94)92759-6/abstract, diakses 21 Juni 2013).
13. Abougalambou SSI, Hassali MA, Sulaiman SAS, et al. Prevalence of
Vascular Complications Among type 2 Diabetes Mellitus Outpatients at
Teaching Hospital in Malaysia. J DiabeteMetab 2011; 2(1): 1-4.
14. Akhter JM, Khan IA, Shahpurkar VV, et al. Evaluation of the Diabetic Foot
According to Wagner's Classification in a Rural Teaching Hospital. The
British Journal of Diabetes and Vascular Disease 2011; 11: 74-79.
15. Steeper R. A Critical Review of the Aetiology of Diabetic Neuropathic
Ulcers. J Wound Care 2005;14(3): 101-3.
16. Omi H, Okayama N, Shimizu M, Fuktomi T, Nakamura A, Imaeda K, et al.
Cilostazol Inhibist High Glucose-Mediated Endothelial-Neutrophil Adhesion
by Decreasing Adhesion Molecule Expression Via NO Production. Microvas
Res 2004;68(2):119-25.
17. Ohba R, Otaka M, Odashima M, Jin M, Komatsu K, Konishi N, et al. Effect
of Cilostazol, a Selective Type-III Phosphodiesterase Inhibitor, on WaterImmersion Stress-Induced Gastric Mucosal Injury in Rats. J Gastroenterol
2006;41(1): 34-40.
18. Kumar V, Cotran RS, Robbins SL. Buku Ajar Patologi Edisi 7 Volume 1.
Jakarta, EGC: 2011.
19. Mackay D, Miller AL. Nutritional Support for Wound Healing. Alternatife
Medicine Review 2003;4(8): 359-377.
20. Diegelmann RF, Evans MC. Wound Healing: An Overview of Acute, Fibrotic
and Delayed Healing. Frontiers in Bioscience 2004;9: 283-289.
21. Thompson PD, Zimet R, Forbes WP, et al. Meta-Analysis of Results from
Eight Randomized, Placebo-Controlled Trials on Yhe Effect of Cilostazol on
Patients with Intermittent Claudication. American Journal of Cardiology
2002; 90(12): 1314-1319.
22. Katzung, B.G. Basic and Clinical Pharmacology 9th edition. USA : Mc Graw
Hill;2005.
23. Keast DH, Bowering CK, Evans AW, et al. Measure: A Proposed Assessment.
Wound Repair Regen 2004;1293 Suppl):S1-17.